Plaque Psoriasis

In this study, investigators assessed how the prescription patterns of biologics, non-biologic systemic agents, and phototherapy are altered after cardiovascular events.

These data underscore the value of individualized cancer risk evaluations when selecting treatment strategies for psoriasis.

A look at 13 phase 2 and phase 3 studies with significant implications from EADV 2025's late-breaking sessions.

Investigators systematically reviewed NB-UVB treatment responses for psoriasis in patients with skin of color.

In this observational analysis, investigators highlight the potential causal link identified between NHHR and psoriasis development.

An audio recap of the top 5 stories in healthcare news from the week of 08/31-9/5.

Investigators highlighted the cardiovascular safety of systemic treatments for psoriasis such as methotrexate and tumor necrosis factor inhibitors.

This analysis highlights bimekizumab’s impact on psoriasis clearance compared to ustekinumab, secukinumab, and adalimumab.

This announcement regarding the new sNDA for roflumilast cream in pediatric patients with psoriasis follows positive findings from the MUSE study.

In this analysis, investigators looked at the importance of skin clearance and daily time trade off (dTTO) among adult patients living with chronic hand eczema (CHE).

This analysis looked at a Hispanic patient cohort, systematically linking specific trichoscopic patterns with clinical outcomes related to scalp psoriasis.

Multidisciplinary management and patient-centered care are critical for optimizing outcomes in complex or severe psoriasis cases.

This analysis suggests that this AI model effectively classifies skin irritation in patch tests, allowing for quicker and more accurate dermatologic assessments.

Up to half of psoriasis patients report significant psychiatric symptoms, highlighting the importance of routine screening in practice.

These findings on teledermatology highlight its effectiveness as a potential solution for disparities in dermatology care within rural communities.

These data on roflumilast cream 0.3% highlight the medication’s efficacy and safety in pediatric patients aged 2 - 11 years.

This study compared the N-NAIL diagnostic tool to NAPSI, highlighting results among patients with nail psoriasis.

This review highlights phase 3 and long-term data on deucravacitinib therapy for patients with plaque psoriasis.

The investigators present pooled findings from the SUNSHINE and SUNRISE trials assessing secukinumab therapy for HS.

In this analysis, evidence which supports a shift in clinical practice using Chinese herbal medicine was explored for atopic dermatitis.

This cohort study suggests that patients with HS treated with adalimumab have an increased risk of infection compared to those with psoriasis.

A study reveals that upadacitinib dose adjustments in atopic dermatitis enhance treatment personalization.

This analysis suggests that GLP-1 RAs provide promise for those with HS and obesity and potentially for such individuals without obesity via immunological impacts.

The G-EPOSS study demonstrated the long-term impacts of guselkumab on patients’ psoriasis symptoms, sexual impairment, and perceived stigmatization.

Findings highlight an association between psoriasis and risks of all-cause, cardiovascular, infection-related, and suicide mortality.